IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Novozymes A/S v DSM IP Assets B.V. [2018] APO 2
Patent Application: 2010270301
Title:Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
Patent Applicant: DSM IP Assets B.V.
Opponent: Novozymes A/S
Hearing Officer: Dr S.D. Barker – Deputy Commissioner of Patents
Decision Date: 5 January 2018
Hearing Date: 29 November 2017, in Canberra
Catchwords: PATENTS – opposition to the grant of a patent – where an opposition is decided in stages, findings of fact in the original decision must be applied in the final determination – original decision found lack of inventive step – this ground has been overcome consistent with the original decision – application proceed to grant
Representation: Counsel for the applicant: Mr B Fitzpatrick
Patent attorney for the applicant: Mr D Longmuir of Phillips Ormonde Fitzpatrick
Counsel for the opponent: Ms K Crooks
Patent attorney for the opponent: Dr J Flattery-O'Brien of Shelston IP Pty Ltd
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2010270301
Title:Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
Patent Applicant: DSM IP Assets B.V.
Date of Decision: 5 January 2018
DECISION
I direct that the application proceed to grant.
I allow the parties an opportunity to provide written submissions in relation to costs according to the following schedule:
DSM IP Assets B.V. is to provide submissions within three (3) weeks from the date of this decision;
Novozymes A/S is to provide submissions in response within five (5) weeks of the date of this decision;
DSM IP Assets B.V. is to provide a reply (if any) within six (6) weeks of the date of this decision.
REASONS FOR DECISION
Patent application number 2010270301 (the present application) was filed on 6 July 2010 under the provisions of the Patent Cooperation Treaty. The applicant is DSM IP Assets B.V. (DSM). An opposition to the grant of a patent was filed by Novozymes A/S (Novozymes). A decision issued on 17 January 2017 (the original decision). [1] The applicant was given an opportunity to amend, and the amendments have been allowed. The opponent asked to be heard in the final determination of the opposition, and a hearing was held on 29 November 2017 in Canberra.
The original decision
The original decision found that claims 1 – 11, 13, 14 and 16 lack inventive step in the light of a document referred to as YJ-9. It is to be noted that there was no finding that claim 12 lacked inventive step. Rather, there was an explicit finding that it had not been shown that claim 12 lacked inventive step:
"Claim 12 is appended to claim 11. The claim specifies that the cell is an inhibitor resistant cell. YJ-9 makes no reference to the cell being inhibitor resistant. There is no evidence that this would have been a matter of routine. It follows that…
Keep reading for free
Create a free CaseChat account to read Novozymes A/S v DSM IP Assets B.V and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2018] APO 2
- Decision Date
CaseChat Overview and Summary
The court considered the legal principles governing the final determination of an opposition decided in stages. It found that a final determination could only consider whether the amendments overcome the deficiencies identified in the original decision, and whether the amendments introduce any new deficiencies. The final determination should be consistent with any relevant findings in the original decision. The court found that the amendments had overcome the deficiencies identified in the original decision, and had not introduced any new deficiencies.
The court found that claim 1 as amended was not lacking in inventive step because the use of an inhibitor resistant cell would not have been a matter of routine. Claims 3 – 13 and claim 24, which were appended to claims 1 or 2, also did not lack inventive step for the same reason. The court found that the amendment had not introduced any new deficiencies.
The court directed the parties to provide written submissions in relation to costs. DSM was to provide submissions within three weeks of the date of the decision, Novozymes was to provide submissions in response within five weeks of the date of the decision, and DSM was to provide a reply within six weeks of the date of the decision. The patent application proceeded to grant.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.